The World Health Organisation said Thursday it will convene a panel of experts in medical ethics next week to explore the use of experimental treatment of Ebola in West Africa.
"Currently there is no registered medicine or vaccine against the virus, but there are several experimental options under development," Xinhua quoted Farhan Haq, the deputy UN spokesman, as saying at a daily news briefing here.
"The World Health Organisation notes that the recent treatment of two health workers with experimental medicine has raised questions," Haq said.
"It stresses that the gold standard for assessing new medicine involves a series of trials in humans, and that the guiding principle with use of any new medicine is 'do no harm'," he added.
"However, Marie-Paule Kieny, assistant director-general at the World Health Organisation, explained that the current situation was unusual and that guidance from medical ethicists was needed," he elaborated.
As a "secret serum" called ZMapp emerged as the primary treatment of two American aid workers infected with Ebola in West Africa, experts warned that it was too early to tell if the treatment is effective.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
